{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T19:49:55Z","timestamp":1776023395350,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81871233"],"award-info":[{"award-number":["81871233"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04004-4","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T08:17:45Z","timestamp":1742199465000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["MS275 induces tumor immunosuppression by upregulating PD-L1 and enhances the efficacy of anti-PD-1 immunotherapy in colorectal cancer"],"prefix":"10.1007","volume":"74","author":[{"given":"Deng","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sihan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqi","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiting","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianxian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"4004_CR1","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.2174\/0929867328666210915105929","volume":"29","author":"N Garmpis","year":"2022","unstructured":"Garmpis N et al (2022) Histone deacetylases and their inhibitors in colorectal cancer therapy: current evidence and future considerations. Curr Med Chem 29:2979\u20132994. https:\/\/doi.org\/10.2174\/0929867328666210915105929","journal-title":"Curr Med Chem"},{"key":"4004_CR2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026831","author":"Y Li","year":"2016","unstructured":"Li Y, Seto E (2016) HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a026831","journal-title":"Cold Spring Harb Perspect Med"},{"key":"4004_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4161\/epi.3.1.5736","volume":"3","author":"JM Mariadason","year":"2008","unstructured":"Mariadason JM (2008) HDACs and HDAC inhibitors in colon cancer. Epigenetics 3:28\u201337. https:\/\/doi.org\/10.4161\/epi.3.1.5736","journal-title":"Epigenetics"},{"key":"4004_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ph15040438","author":"M Mayer","year":"2022","unstructured":"Mayer M et al (2022) Preclinical efficacy and toxicity analysis of the pan-histone deacetylase inhibitor gossypol for the therapy of colorectal cancer or hepatocellular carcinoma. Pharmaceuticals. https:\/\/doi.org\/10.3390\/ph15040438","journal-title":"Pharmaceuticals"},{"key":"4004_CR5","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1002\/1878-0261.12953","volume":"15","author":"W Blaszczak","year":"2021","unstructured":"Blaszczak W et al (2021) Immune modulation underpins the anti-cancer activity of HDAC inhibitors. Mol Oncol 15:3280\u20133298. https:\/\/doi.org\/10.1002\/1878-0261.12953","journal-title":"Mol Oncol"},{"key":"4004_CR6","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1093\/oncolo\/oyac078","volume":"27","author":"TB Karasic","year":"2022","unstructured":"Karasic TB et al (2022) Phase I trial of regorafenib, hydroxychloroquine, and entinostat in metastatic colorectal cancer. Oncologist 27:716-e689. https:\/\/doi.org\/10.1093\/oncolo\/oyac078","journal-title":"Oncologist"},{"key":"4004_CR7","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.biocel.2007.02.009","volume":"39","author":"H Hess-Stumpp","year":"2007","unstructured":"Hess-Stumpp H, Bracker TU, Henderson D, Politz O (2007) MS-275, a potent orally available inhibitor of histone deacetylases\u2013the development of an anticancer agent. Int J Biochem Cell Biol 39:1388\u20131405. https:\/\/doi.org\/10.1016\/j.biocel.2007.02.009","journal-title":"Int J Biochem Cell Biol"},{"key":"4004_CR8","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.2217\/fon-2016-0526","volume":"13","author":"RM Connolly","year":"2017","unstructured":"Connolly RM, Rudek MA, Piekarz R (2017) Entinostat: a promising treatment option for patients with advanced breast cancer. Future Oncol 13:1137\u20131148. https:\/\/doi.org\/10.2217\/fon-2016-0526","journal-title":"Future Oncol"},{"key":"4004_CR9","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3892\/ijo_00000406","volume":"35","author":"TU Bracker","year":"2009","unstructured":"Bracker TU et al (2009) Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models. Int J Oncol 35:909\u2013920. https:\/\/doi.org\/10.3892\/ijo_00000406","journal-title":"Int J Oncol"},{"key":"4004_CR10","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.4049\/jimmunol.1700105","volume":"199","author":"L Zheng","year":"2017","unstructured":"Zheng L et al (2017) Microbial-derived butyrate promotes epithelial barrier function through IL-10 receptor-dependent repression of claudin-2. J Immunol 199:2976\u20132984. https:\/\/doi.org\/10.4049\/jimmunol.1700105","journal-title":"J Immunol"},{"key":"4004_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232415539","author":"Y Kim","year":"2022","unstructured":"Kim Y et al (2022) Immunomodulation of HDAC inhibitor entinostat potentiates the anticancer effects of radiation and PD-1 blockade in the murine Lewis lung carcinoma model. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232415539","journal-title":"Int J Mol Sci"},{"key":"4004_CR12","doi-asserted-by":"publisher","first-page":"e7085","DOI":"10.1371\/journal.pone.0007085","volume":"4","author":"B Vire","year":"2009","unstructured":"Vire B et al (2009) Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4\u20131BBL\/4-1BB immunomodulatory functions. PLoS ONE 4:e7085. https:\/\/doi.org\/10.1371\/journal.pone.0007085","journal-title":"PLoS ONE"},{"key":"4004_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18091883","author":"M Mrakovcic","year":"2017","unstructured":"Mrakovcic M, Kleinheinz J, Frohlich LF (2017) Histone deacetylase inhibitor-induced autophagy in tumor cells: implications for p53. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms18091883","journal-title":"Int J Mol Sci"},{"key":"4004_CR14","doi-asserted-by":"publisher","first-page":"eadd3243","DOI":"10.1126\/sciadv.add3243","volume":"9","author":"LJ Eichner","year":"2023","unstructured":"Eichner LJ et al (2023) HDAC3 is critical in tumor development and therapeutic resistance in Kras-mutant non-small cell lung cancer. Sci Adv 9:eadd3243. https:\/\/doi.org\/10.1126\/sciadv.add3243","journal-title":"Sci Adv"},{"key":"4004_CR15","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/mc.23551","volume":"62","author":"RM Peter","year":"2023","unstructured":"Peter RM et al (2023) Histone deacetylase inhibitor belinostat regulates metabolic reprogramming in killing KRAS-mutant human lung cancer cells. Mol Carcinog 62:1136\u20131146. https:\/\/doi.org\/10.1002\/mc.23551","journal-title":"Mol Carcinog"},{"key":"4004_CR16","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1182\/blood-2006-05-021873","volume":"109","author":"I Gojo","year":"2007","unstructured":"Gojo I et al (2007) Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109:2781\u20132790. https:\/\/doi.org\/10.1182\/blood-2006-05-021873","journal-title":"Blood"},{"key":"4004_CR17","doi-asserted-by":"publisher","first-page":"968","DOI":"10.3324\/haematol.2016.142406","volume":"101","author":"CL Batlevi","year":"2016","unstructured":"Batlevi CL et al (2016) ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma. Haematologica 101:968\u2013975. https:\/\/doi.org\/10.3324\/haematol.2016.142406","journal-title":"Haematologica"},{"key":"4004_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejphar.2009.10.033","volume":"627","author":"S Flis","year":"2010","unstructured":"Flis S, Gnyszka A, Flis K, Splawinski J (2010) MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells. Eur J Pharmacol 627:26\u201332. https:\/\/doi.org\/10.1016\/j.ejphar.2009.10.033","journal-title":"Eur J Pharmacol"},{"key":"4004_CR19","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.bbrc.2009.07.017","volume":"387","author":"S Flis","year":"2009","unstructured":"Flis S, Gnyszka A, Splawinski J (2009) HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines. Biochem Biophys Res Commun 387:336\u2013341. https:\/\/doi.org\/10.1016\/j.bbrc.2009.07.017","journal-title":"Biochem Biophys Res Commun"},{"key":"4004_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010098","author":"S Lamoine","year":"2021","unstructured":"Lamoine S et al (2021) The class I HDAC inhibitor, MS-275, prevents oxaliplatin-induced chronic neuropathy and potentiates its antiproliferative activity in mice. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23010098","journal-title":"Int J Mol Sci"},{"key":"4004_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040634","author":"R Jenke","year":"2021","unstructured":"Jenke R, Ressing N, Hansen FK, Aigner A, Buch T (2021) Anticancer therapy with HDAC inhibitors: mechanism-based combination strategies and future perspectives. Cancers. https:\/\/doi.org\/10.3390\/cancers13040634","journal-title":"Cancers"},{"key":"4004_CR22","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1158\/2326-6066.CIR-18-0070","volume":"6","author":"BJ Christmas","year":"2018","unstructured":"Christmas BJ et al (2018) Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs. Cancer Immunol Res 6:1561\u20131577. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0070","journal-title":"Cancer Immunol Res"},{"key":"4004_CR23","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1002\/cncr.31761","volume":"124","author":"HJ Smith","year":"2018","unstructured":"Smith HJ et al (2018) The antitumor effects of entinostat in ovarian cancer require adaptive immunity. Cancer 124:4657\u20134666. https:\/\/doi.org\/10.1002\/cncr.31761","journal-title":"Cancer"},{"key":"4004_CR24","doi-asserted-by":"publisher","DOI":"10.20517\/2347-8659.2018.58","author":"CJ Yelton","year":"2018","unstructured":"Yelton CJ, Ray SK (2018) Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma. Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.20517\/2347-8659.2018.58","journal-title":"Neuroimmunol Neuroinflamm"},{"key":"4004_CR25","doi-asserted-by":"publisher","first-page":"689896","DOI":"10.3389\/fimmu.2021.689896","volume":"12","author":"H Shaikh","year":"2021","unstructured":"Shaikh H et al (2021) Mesenteric lymph node transplantation in mice to study immune responses of the gastrointestinal tract. Front Immunol 12:689896. https:\/\/doi.org\/10.3389\/fimmu.2021.689896","journal-title":"Front Immunol"},{"key":"4004_CR26","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/mi.2015.77","volume":"9","author":"SA Houston","year":"2016","unstructured":"Houston SA et al (2016) The lymph nodes draining the small intestine and colon are anatomically separate and immunologically distinct. Mucosal Immunol 9:468\u2013478. https:\/\/doi.org\/10.1038\/mi.2015.77","journal-title":"Mucosal Immunol"},{"key":"4004_CR27","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3389\/fonc.2020.00485","volume":"10","author":"X Liu","year":"2020","unstructured":"Liu X et al (2020) HDAC10 is positively associated with PD-L1 expression and poor prognosis in patients with NSCLC. Front Oncol 10:485. https:\/\/doi.org\/10.3389\/fonc.2020.00485","journal-title":"Front Oncol"},{"key":"4004_CR28","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1007\/s12253-020-00834-y","volume":"26","author":"L Hegedus","year":"2020","unstructured":"Hegedus L et al (2020) HDAC inhibition induces PD-L1 expression in a novel anaplastic thyroid cancer cell line. Pathol Oncol Res 26:2523\u20132535. https:\/\/doi.org\/10.1007\/s12253-020-00834-y","journal-title":"Pathol Oncol Res"},{"key":"4004_CR29","doi-asserted-by":"publisher","first-page":"573547","DOI":"10.3389\/fonc.2021.573547","volume":"11","author":"G Cui","year":"2021","unstructured":"Cui G (2021) The mechanisms leading to distinct responses to PD-1\/PD-L1 blockades in colorectal cancers with different MSI statuses. Front Oncol 11:573547. https:\/\/doi.org\/10.3389\/fonc.2021.573547","journal-title":"Front Oncol"},{"key":"4004_CR30","doi-asserted-by":"publisher","first-page":"5461","DOI":"10.1002\/jcp.29494","volume":"235","author":"Z Payandeh","year":"2020","unstructured":"Payandeh Z et al (2020) PD-1\/PD-L1-dependent immune response in colorectal cancer. J Cell Physiol 235:5461\u20135475. https:\/\/doi.org\/10.1002\/jcp.29494","journal-title":"J Cell Physiol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04004-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04004-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04004-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T06:48:50Z","timestamp":1745736530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04004-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["4004"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04004-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4133957\/v1","asserted-by":"object"}]},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"20 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal experiments were performed in line with International Guidelines and Protocols. This study and included experimental procedures were approved by the Institutional Animal Care and Use Committee of Sichuan University. All animal housing and experiments were conducted in strict accordance with the institutional guidelines for care and use of laboratory animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participation"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"150"}}